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The Cancer Research Institute (CRI) iAtlas is an interactive web 
platform for data exploration and discovery in the context of tumors 
and their interactions with the immune microenvironment. iAtlas 
allows researchers to study immune response characterizations and 
patterns for individual tumor types, tumor subtypes, and immune 
subtypes. iAtlas supports computation and visualization of 
correlations and statistics among features related to the tumor 
microenvironment, cell composition, immune expression signatures, 
tumor mutation burden, cancer driver mutations, adaptive cell 
clonality, patient survival, expression of key immunomodulators, and 
tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched 
to accompany the release of the TCGA PanCancer Atlas and has since 
been expanded to include new capabilities such as (1) user-defined 
loading of sample cohorts, (2) a tool for classifying expression data 
into immune subtypes, and (3) integration of TIL mapping from digital 
pathology images. We expect that the CRI iAtlas will accelerate 
discovery and improve patient outcomes by providing researchers 
access to standardized immunogenomics data to better understand 
the tumor immune microenvironment and its impact on patient 
responses to immunotherapy.
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Introduction
Immuno-oncology (IO) is one of the most promising areas of 
cancer research, with IO-based treatments demonstrating high 
efficacy within certain cancer types and subsets of patients1–4. 
To broaden the utility of these therapies to more patients, fun-
damental research is required to improve our understanding of 
tumor-immune interactions—allowing the next-generation 
of therapeutics and treatment strategies to emerge4. Advances 
in the IO field are impeded by the inaccessibility of IO study 
data and results and lack of data standardization, limiting the 
ability to easily compare results across studies. This has led to 
the underutilization of existing data, unnecessary study dupli-
cation, and failure to achieve rapid consensus in the field5. With 
the vast increase in the number and scope of IO projects 
expected in the coming years combined with widespread adop-
tion of genomics and other high dimensional technologies, these 
problems will be compounded going forward.
We developed the Cancer Research Institute (CRI) iAtlas 
portal (https://www.cri-iatlas.org) to integrate IO research data, 
with the goal of providing an interactive, exploratory hub for 
the IO research community. In doing so, we hope to improve the 
accessibility and utility of critical resources generated from 
IO studies. iAtlas is a set of analytic modules—hosted on the 
web—for studying interactions between tumors and the immune 
microenvironment. These modules allow researchers to explore 
associations among a variety of immune characterizations 
as well as with genomic and clinical phenotypes.
The initial release of iAtlas (April 5, 2018) provided a rich 
resource to complement analysis results from The Cancer Genome 
Atlas (TCGA) Research Network on the TCGA data set com-
prising over 10,000 tumor samples and 33 tumor types6 (“The 
Immune Landscape of Cancer”; here referred to as “Immune 
Landscape”). This study identified six immune subtypes that 
span cancer tissue types and molecular subtypes, and found that 
these subtypes differ by somatic aberrations, microenvironment, 
and survival. Per-sample characterizations included total lym-
phocytic infiltrate (from DNA methylation as well as H&E imag-
ing data), estimated cell type fractions, immune gene signature 
expression, MHC/HLA type and expression, antigen presenta-
tion machinery, T cell and B cell receptor repertoire inference, 
viral/microbial characterization, associations with pathway 
disruption and activity, and other analysis results. The 
Immune Landscape6 manuscript reported on the most novel and 
potentially therapeutically salient statistical associations between 
these immune subtypes and the results of the immune characteri-
zation. We have continued to develop and evolve the CRI iAtlas 
application; here, we report the technical design and imple-
mentation of iAtlas up to and including the recently released 
version 1.27. This version includes new features requested 
by users including: (1) user-defined loading of sample cohorts, 
(2) a tool for classifying expression data into immune subtypes, 




iAtlas is a web-based application to enable data exploration 
for clinicians, biologists, and informaticists. The inputs and 
architecture of the application are described below.
Data
The iAtlas app uses structured data and outputs from the Immune 
Landscape6 study and the TCGA PanCancer Atlas initiative8, 
which harmonized TCGA data, ensuring uniform quality con-
trol and sample inclusion, batch effect detection, normalization 
across platforms, combination mutation calling from multiple 
centers, and robustly compiled clinical and outcome data. A key 
source of iAtlas data is the table summarizing tumor-sample and 
immune characterizations for 11,080 TCGA patient participants 
of the TCGA, Table S1 of the Immune Landscape6 manuscript, 
here termed the “PanImmune Feature Matrix”. Auxiliary data 
were sourced from files available on this manuscript’s data page 
at the NCI Genomic Data Commons, from the TCGA PanCancer 
Atlas Data Mirror, and from the TCGA PanCancer Atlas working 
space in Synapse (see Data availability). iAtlas data were format-
ted as data frames (tables) and stored as “feather” files (https:// 
github.com/wesm/feather) on the application server for fast 
loading (Table 1).
Table 1. iAtlas data files.
Filename Description
fmx_df.feather All immune readout features/variables (11,080) across samples (139).
feature_df.feather Additional annotations for a subset (104) features.
feature_method_df.feather Annotation of methods (21) used to compute features.
im_direct_relationships.
feather Annotation and source of immunomodulators genes (79).
im_expr_df.feather Gene expression for immunomodulators genes (76) across samples (9,693).
im_potential_factors.
feather Additional genes (97) that have potential to be involved in immune modulation.
io_target_annotations.
feather Annotation of immuno-oncology target genes (405).
io_target_expr_df.feather Gene expression for immuno-oncology target genes (401) across samples (9,693)
sample_group_df.feather Annotation of the sample groups (137 - TCGA studies, TCGA cancer subtypes and 
Immune Subtypes). 
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Annotation and browsing of the PanImmune Feature 
Matrix: iAtlas includes a Data Description page with details on 
all variables presented in individual modules, with the abil-
ity for users to “drill down” on related groups of variables to 
understand how values were derived. Variables are listed in a 
text-searchable table containing the name of the variable, the 
‘Variable Class’, the unit (if applicable), and whether the vari-
able is numeric or categorical. A ‘Variable Class’ is the name of a 
group of variables that are of similar type and are often the result 
of one particular analysis. Clicking on a row exposes a list of 
all variables in the ‘Variable Class’ and provides links to text 
descriptions of the analysis methods used to generate the 
variables.
R/Shiny architecture
iAtlas is powered by Shiny9 and makes extensive use of Shiny 
Modules10 to organize code into composable units (Figure 1). 
Each iAtlas Analysis module is designed as a Shiny mod-
ule, allowing simple integration of new analytical functionality. 
iAtlas uses the tidyverse11 family of R packages (e.g., dplyr12, 
tidyr13, purrr14, stringr15, tibble16) as well as the wrapr17 pack-
age to assist with tidy evaluation. These functions power the 
data transformations of internal tabular data that are then used to 
create the interactive plots (i.e., with the plotly18 graphing 
library) and data tables (via the DT19 wrapper to the DataTables 
library) seen through the iAtlas modules. We also make heavy 
use of the crosstalk20 package to enable event-driven updates 
Figure 1. iAtlas architecture overview. (A) Structured data from immunogenomic analyses, including the Immune Landscape6 study and 
expanding over time, are organized and stored as flat (i.e., feather) files within Synapse and made available alongside the application code 
in GitHub. (B) Tabular data from feather files are read from disk into memory to drive all operations related to sample groupings, sample-level 
immune characterizations (readouts), and more granular—and high dimensional—assay measurements. (C) The core application code is 
built as a catalog of Shiny Modules, each of which encapsulates logic for data transformation and visualization related to a scientific theme 
or assay type. (D) Analysis modules, tools, and data description views are hosted in a unified application on shinyapps.io; the layout and 
connectivity between modules in the iAtlas Explorer space are managed by the shinydashboard21 library.
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to the application state. The core iAtlas application is hosted 
on https://shinyapps.io.
Analysis modules
The main feature of the iAtlas interface is the iAtlas 
Explorer (Figure 2, found under the EXPLORE tab), which pro-
vides several Analysis modules to explore and visualize results. 
Each module supports a type of exploration, with interactive 
views and controls to enhance and extend the results and analyt-
ics as initially described in the Immune Landscape6 study. The 
layout of pages and sections within the iAtlas Explorer is driven 
by the shinydashboard21 package.
Within each module in iAtlas, results are displayed relative to 
Sample Groups, corresponding to defined study cohorts. Sev-
eral Sample Groups options are pre-loaded in the tool: first, 
TCGA tumor type (TCGA Study), which are the standard 
TCGA tumor types collected and designated by the TCGA. Sec-
ond, TCGA tumor subtypes (TCGA Subtype), a compendium 
of further subdivision of TCGA studies into molecular 
subtypes according to publications by the TCGA Research 
Network22. Finally, a division of tumor samples into distinct 
patterns of immune response in cancer (Immune Subtypes) is 
provided6. The choice of Sample Groups is global across all 
modules but can be updated at any time via the Select Sample 
Groups element in the side menu. We also allow users to upload 
custom-grouped samples and analyze those with iAtlas mod-
ules. The selection of a sample group defines the samples utilized 
in all analysis modules. For convenience, group annotations 
can be displayed in visualizations within each module.
 Sample Group Overview: View summary information for 
user-selected sample cohort groups. There are currently three 
sections: Custom Groups, Group Key, and Group Overlap. 
Respectively, these sections permit loading of user-defined 
sample groups, review of detailed annotations of sample 
groups in a table, and display of overlap between different 
types of groupings in a mosaic plot.
 Tumor Microenvironment: Explore immune cell proportions 
in sample groups with two sets of faceted bar charts, one for 
overall cellular proportions (i.e., leukocyte, stromal, and tumor 
fraction) and one for computed immune cell proportions 
(e.g., monocytes, CD8+ T cells, naive B cells).
 Immune Feature Trends: Visualize how immune readouts 
vary across sample groups. Violin or box plots show the dis-
tribution of individual values across samples in each group, 
while heatmaps and scatter plots can be used to explore the 
correlation between any pair of variables within each group.
 Clinical Outcomes: Quantify the relationship between immune 
response and disease outcome, in terms of either overall 
survival (OS) or progression free interval (PFI)23. Results are 
displayed as Kaplan Meier plots as well as heat maps showing 
the concordance index between variables and survival.
 Immunomodulators: Explore the expression of genes 
coding for immunomodulating proteins6, which include 
therapeutically important immune checkpoint proteins. 
Immunomodulators are organized by grouping into three 
categories: Gene Family (such as “TNF”, “MHC Class II”, 
“Immunoglobulin”, or “CXC chemokine”), Super Category 
(such as “Ligand”, “Receptor”, or “Antigen presenta-
tion”), and Immune Checkpoint (classified as “Inhibitory” 
or “Stimulatory”). Violin and box plots are again used to 
present distributions, and a table provides additional metadata 
about immunomodulator genes.
 Driver Associations: Test and visualize associations 
between mutations and IO-related response variables. In 
the Immune Landscape6 study, we reported somatic driver 
alterations that are correlated with increases or decreases 
in overall immune cell content, or with the fraction of 
individual immune cell types. These and other variables 
can be selected to calculate the significance of relationships 
in each sample group and view results in a volcano 
plot.
 TIL Maps: We used the results of a recently reported 
method to assess which spatial regions of hematoxylin and 
eosin (H&E) whole slide images show evidence of tumor- 
infiltrating lymphocytes (TILs)24. The method, which uses 
deep learning, was applied to thousands of H&E slides of 
the TCGA, allowing slides to be characterized in terms 
of TIL density and patterns.
Integration with Landscape of IO Drug Target Devel-
opment: CRI has compiled and published comprehensive 
overviews describing ongoing immunotherapy drug trials, includ-
ing targets, agents, and tumor sites and has made summaries 
available in an online resource, the Immune-Oncology Landscape 
(IO Landscape) (www.cancerresearch.org/IO-landscape)25–28. 
The iAtlas and the IO Landscape resource have been inter-
linked, enabling researchers to more readily understand the 
relationship between targeted proteins in IO therapy and the 
behavior of those targets in tumor tissue.
 In IO Target Gene Expression Distributions, the distribu-
tion of gene expression values for the selected IO target, 
by sample group, is displayed in violin plots. Clicking 
on the expression distribution (violin plot) of a particular 
sample group, a histogram of the values is displayed.
 The IO Target Annotations section provides a searchable 
table with IO targets and associated annotations. In the 
rightmost column, a link is provided to a view of the 
IO Landscape page, the selected target is highlighted in 
summary barcharts showing the number of agents and cancer 
types being studied for that target.
In the opposite direction, clicking on targets in the barcharts in 
the IO Landscape on CRI web pages brings up the target gene 
expression in iAtlas.
Tools
iAtlas Tools are accessible via the TOOLS tab on the iAtlas 
Portal. Modules in this space of the portal enable users to “bring 
their own data” for processing through immunogenomic algo-
rithms that drive some of the results presented in the Analysis 
modules described above.
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Figure 2. iAtlas Explorer. A range of Analysis modules (blue boxes above) are available that span from clinical to molecular and imaging 
data types. Within each module, interactive controls allow researchers to expand views, exposing underlying data and results. Settings 
are available (green box above) to select the sample groupings (TCGA Study, Disease Subtype, or Immune Subtype) which then 
propagate through modules.
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Immune Subtype Prediction: This tool performs classification 
of RNA-seq data into one of six immune subtypes as described 
in the Immune Landscape6 study. Using a new ensemble model 
based on XGBoost29, researchers can upload their own data 
for classification30. Each member of the ensemble was trained 
on a random subset of previously reported immune subtypes6 
and features (described below) based on gene expression data 
from the TCGA PanCancer Atlas Initiative8. All code and 
methods have been confirmed as reproducible. An R package is 
available on GitHub (https://github.com/CRI-iAtlas/ImmuneSub-
typeClassifier)30.
The submitted expression data—subsetted to the 485 genes 
that comprised the 5 signatures that produced the immune 
subtypes—are used to generate robust features of three types: 
quartiles, binary gene-pairs, and signature-pairs. For example, 
given a single sample, genes are binned into quartiles and given 
a bin label (quartile features). Then, similar to the “Top Scoring 
Pairs” classifier31, genes are paired, and given binary values 









. Lastly, signature-pair features are calculated using 











 is gene i from signature m, g
jn
 is gene j from signature 
n, and k is the number of gene pairs considered resulting 
in a value between 0 and 1. The features are computed 
independently for each sample, and do not require normalization 
across samples. These features are given to a trained XGBoost 
classifier which returns a probability of being in any of the 
six subtypes. Lastly, a “best call” is made with a final trained 
XGBoost classifier using the six probabilities as input. To vali-
date the robustness of the classifier, TCGA data were processed 
using four different software pipelines and normalization, 
showing that classification performance was independent of the 
gene expression quantification method30. Along with a down-
loadable table of results, visualizations are also provided. This 
tool is a convenient way for researchers to apply the meth-
ods of the Immune Landscape6 study to their own data without 
difficult statistical coding.
Operation
To use iAtlas, access the web app via https://www.cri-iatlas.org. 
The software can also be run locally on all platforms (Windows, 
Mac, Linux). To run the Shiny app locally, a working R instal-
lation with necessary libraries is required and an installation 
of RStudio is recommended.
To install and run the app locally:
1.   Clone shiny-iatlas GitHub repository
      (git clone https://github.com/CRI-iAtlas/shiny-iatlas)
2.    Open shiny-iatlas.Rproj in RStudio
3.    Install packages. In the RStudio console, run:
       renv::restore()
4.    Start the app by running:
        shiny::runApp()
Use cases
Reproducing published results and gaining information on 
underlying data
One of the initial motivations behind iAtlas was to provide 
an interactive platform that is able to reproduce figures published 
in the Immune Landscape6 manuscript but expands that with 
the ability to generate variations of those figures, for other 
choices of tumor samples and immune readouts of interest. As an 
example, in order to reproduce Figure 4A from the Immune 
Landscape6 publication, which shows the correlation of DNA 
damage measures with the fraction of leukocytes in the 
tumor, we began by selecting the EXPLORE tab. We then 
opened the Immune Feature Trends module and selected the 
“Immune Subtype” option under Select Sample Groups 
in the Explorer Settings panel in the left menu. In the ensuing 
module page, at the Correlations section (Figure 3), we selected 
the “DNA Alterations” under Select or Search for 
Variable Class, “Leukocyte Fraction” under Select or 
Search for Response Variable, and the “Spearman” method 
under Select or Search for Correlation Method 
(each a separate dropdown menu). This produced a heatmap iden-
tical in content to Figure 4A in the Immune Landscape6 publica-
tion. However, the heatmap provides additional information on 
underlying data via interactivity: by clicking on a heatmap-cell, 
the underlying data is displayed in a scatterplot. Hovering a cursor 
over a point in the scatter plot reveals sample-level information.
Table 2 lists the particular manuscript figures (from the Immune 
Landscape6 publication) that can be reproduced or adapted 
to specific research questions.
Exploring new IO results
With the iAtlas portal, scientists can explore and answer new 
questions based on specific research interests. For example, we 
asked: “What is the expression level of PD-L1, a therapeutically 
important protein, in subtypes of breast cancer?” To answer this 
question, from the landing page, we first selected the “TCGA 
Subtype” sample group, followed by the “Breast Invasive 
Carcinoma (BRCA)” study subset. Next, we selected the Immu-
nomodulators module (Figure 4). Based on a very quick 
scan of the drop down, we didn’t see any names that matched 
our gene of interest, so we scrolled further down on the page to 
view the table of ‘Immunomodulator Annotations’. By typing in 
the first few letters of a gene name (e.g., “PD...”) into the ‘Search’ 
field, the table was filtered to a set of matching genes, and 
we could see that “PD-L1” is the Friendly Name for the gene 
“CD274” (the approved gene symbol on genenames.org). After 
returning to the Select or Search for Variable drop 
down menu above and selecting “CD274 (PD-L1)”, we 
were able to see a display of violin plots showing the distribu-
tions of gene expression across BRCA molecular subtypes. We 
could then visually compare distributions between subtypes, 
noticing for example the elevated expression level in the Her2 
subtype compared to Basal breast cancer. These comparisons 
can guide further characterization not only of how gene expres-
sion can differ between TCGA subtypes of breast cancer, but 
also how these subtype-specific differences might correlate with 
clinical outcomes, as investigated in other studies32–34. Using 
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Table 2. Immune Landscape figures in iAtlas. iAtlas 
Analysis module (Column 1) and examples of figure 
panels (Column 2) in the Immune Landscape6 manuscript 
that can be generated using the module. Researchers 
can use this as a starting point for tailoring figures to their 
own interests.
iAtlas Analysis module Immune Landscape figures
Sample Group Overview 1D, S1B 
Tumor Microenvironment 2A, 2C, S2A 
Immune Feature Trends 1C, 2B, 4A




Figure 3. Visualization of the correlation of DNA damage in cancer with the degree of immune cell infiltration. Top right: Original 
manuscript figure panel from the Immune Landscape6 study. Bottom left: Equivalent figure generated in iAtlas. By selecting a specific 
heatmap cell (highlighted), the underlying data is displayed (Bottom right), using the selections shown. Individual points can be selected to 
get sample IDs and additional information (blue box).
Figure 4. Visualization of the PD-L1 immunomodulator expression patterns in breast cancer subtypes. Selection for PD-L1 expression 
distributions displayed as violin plots within molecular subtypes of breast cancer, according to “PAM-50” classification. Elevated expression 
is seen in the HER2 subtype.
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this module and others, the researcher has the ability to answer 
new questions which could lead to developments in oncology 
research.
Classification of immune subtypes on new data
In order to classify any tumor-derived gene expression sam-
ples into immune subtypes6,30, users can select the TOOLS tab 
(top right), which leads to an interface containing notes, sev-
eral links and the controls. In order to classify new data, we 
submitted data as a text file, in this case tab separated, with 
the first column containing gene IDs and later columns con-
taining samples. A provided example file can be found in the 
description text. The first row of the data was a header con-
taining sample IDs. Gene IDs can be either HGNC gene 
symbols (preferred), Entrez ID, or Ensembl identifiers. The 
locally available data was selected using the Browse button, and 
the file delimiter was selected, along with gene ID type, using 
drop down menus. Hitting the GO button produced classifica-
tions, signature scores, and cluster probabilities, which were 
reported in a table that was downloaded as a csv, xlsx, or pdf file. 
In addition, a barplot with the frequency of predicted subtypes 
for the submitted data was displayed.
All data required to run the application and describe the Use 
Cases are available in GitHub and archived with Zenodo7.
Conclusions
CRI iAtlas is a platform that facilitates analysis and exploration 
of the tumor immune microenvironment by making IO-related 
data and tools accessible to the research community. iAtlas 
builds upon the comprehensive TCGA analysis of tumor-
immune interactions on 10,000 tumors and illustrates how 
commonalities and differences of the immune response across 
33 tumor types can provide clues for advancing therapeutics. 
iAtlas provides researchers with the tools to dive deeper into 
immunogenomic and clinical data and to develop and refine 
hypotheses regarding tumor-immune interactions that will 
empower researchers to gain insight and design the next 
generation of immuno-oncology treatment strategies.
Data availability
Source data
Original data files from the TCGA PanCancer Atlas publication 
can be found in the NCI Genomic Data Commons (https://gdc.
cancer.gov/about-data/publications/panimmune) or the TCGA 
PanCancer Atlas Data Mirror (https://isb-cancer-genomics-cloud.
readthedocs.io/en/latest/sections/PanCancer-Atlas-Mirror.html.
Extended data
Zenodo: CRI iAtlas (Version 1.2.0). https://doi.org/10.5281/ 
zenodo.39267577.
Folder ‘Data’ contains all data required to run the application 
and describe Use Cases. This is also available on GitHub.
License: Apache License 2.0.
Software availability
Source code is available from GitHub: https://github.com/ 
CRI-iAtlas/shiny-iatlas.
Source code for the specific version described at the time of 
publication: https://github.com/CRI-iAtlas/shiny-iatlas/releases/
tag/v1.2.0.
Archived source code at the time of publication: https://doi.
org/10.5281/zenodo.39267577.
Hosted iAtlas application on shinyapps.io: https://isb-cgc.shin-
yapps.io/shiny-iatlas.
Pinned version of the hosted iAtlas app described at the time 
of publication: https://isb-cgc.shinyapps.io/iatlas_v1-2.
License: Apache License 2.0.
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In their manuscript, Eddy et al. describe the interactive data portal iAtlas that accompanies the 
authors’ 2018 publication in Immunity, “The Immune Landscape of Cancer”. In that seminal paper, 
the authors present a compendium of analyses they performed to interrogate the diversity of 
immune states across human cancers using publicly available data from The Cancer Genome Atlas 
(TCGA). While the Immunity manuscript described the identification and characterization of six 
distinct “Immune Subtypes” and highlighted examples of key distinguishing features of the data 
sets, the accompanying iAtlas tool enables users to explore these rich analyses on their own, using 
parameters of their choosing. Comprising over 11,000 patients across 33 cancer types, these data 
represent an exceptionally comprehensive patient cohort from which a wide range of 
immunological insights can be gleaned. 
 
iAtlas, which is available as both a web-based Shiny app and for offline implementation in R from 
GitHub, is a remarkably powerful and user-friendly portal through which researchers can easily 
interrogate the TCGA datasets for all of the immune analyses presented in their manuscript. The 
platform allows users to group their analyses by examining differences across TCGA cancer types, 
tumor subtypes (e.g. Luminal A vs. Her2 breast cancers), or their six defined Immune Subtypes. 
Furthermore, they have included the ability for users to define their own subsets and perform all 
of the included analyses across these subsets. The analyses within iAtlas include cellular readouts 
(e.g. degree of immune infiltration, fractions of particular leukocyte populations), molecular 
readouts (e.g. proliferation rates, gene expression, SNVs, CNAs, etc.), lymphocyte receptor 
(TCR/BCR) repertoires, network analyses, and tissue-level analyses (e.g. architectural 
characteristics). These variables can be investigated in the context of a wide range of parameters 
(e.g. clinical outcomes, correlations to driver gene mutations, etc.), designated as distinct modules, 
rendering the tool incredibly powerful with a near limitless number of potential questions to 
investigate in the field of tumor immunology. iAtlas is a remarkable tool with an extremely rich 
associated dataset whose elegant and straight-forward implementation render it accessible to 
researchers of all computational abilities. 
 
I have no major concerns with this manuscript. What follows are a list of comments, minor 
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concerns, and suggestions that should not preclude acceptance of the manuscript but rather 
serve as potential items to include in future releases of iAtlas:
In the Cell Type Fractions of the Tumor Microenvironment module, it would be helpful to 
include an option for the user to select which CIBERSORT immune types to include as a 
custom “Cell Fraction Type”. For example, a user could select only memory resting CD4 T 
cells, memory activated CD4 T cells, naïve CD4 T cells, Tregs, and Tfh if they wanted to easily 
visualize the relative fractions of particular Th subsets within the CD4 compartment across 
groups. In some instances, it may be more biologically meaningful to compare these shifts 




In the Tumor Microenvironment module, when comparing leukocyte fraction to the total 
stromal fraction, there are typically a small number of samples where the leukocyte fraction 
exceeds the total stromal fraction, denoted as “estimation artifacts”. What is the source of 
these artifacts? It may help to include a description of this in the legend. 
 
2. 
As a general comment, in a variety of instances it might be informative if there would be a 
way to include statistics between groups, though I recognize that doing so could be 
computationally intensive and invalid in many instances. Nonetheless, given the large 
sample sizes I am often left wondering if modest differences between groups are 
statistically meaningful and where inferences can be drawn (e.g. an increase in Treg fraction 
from 0.024 in the “Inflammatory” subtype to 0.029 in the “TGF-b Dominant” subtype). 
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The Data Description tab might be aided by including a sentence or phrase within the table 
stating what each variable is without requiring following all of the methods links. For 
example, I am assuming the BCR/TCR Shannon incorporates both the richness and 
evenness to depict the diversity of the repertoire, but it might be helpful to state the 
meaning of the terms in the table. 
 
4. 
For the Clinical Outcomes, it might be useful to include “Immune Subtypes” as a variable 
when analyzing TCGA Study so that users can evaluate the survival probabilities depending 
on immune subtype for a given cancer. 
 
5. 
There appears to be a minor issue wherein no results can be displayed for the Concordance 
Index of the Clinical Outcomes analyses for most, if not all, variables when using TCGA 
Study for the Sample Groups. 
 
6. 
The TIL Maps module is quite impressive and the ability to examine the histology from each 
of the patients along with the calculated metrics is an outstanding feature. Nonetheless, 
when one clicks one of the violin plots, the annotation lists seems only to display an 
individual patient rather than the entire list of patients for that group. 
 
7. 
The Immune association with driver gene analysis is a powerful tool whose insights have 
far-reaching implications and represent an active area of research in tumor immunology. 
While the interactive volcano plot is highly informative and useful for identifying genes of 
interest, it would also be useful to be able to run the analysis in the opposite direction. If 
possible, it would be informative to be able to select a driver gene and see where it lies in 
the various volcano plots and which of the variables are correlated with the mutation.
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This article presents CRI iAtlas, a website with a suite of interactive tools for exploring and 
visualizing tumor immune microenvironment data collected by The Cancer Genome Atlas project.  
 
It is based on robust, well-established R packages that are widely used for filtering, analysing and 
displaying large, multi-faceted data sets of the type used here. 
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The design and implementation of the website are well described and the underlying code and 
data provided in readily accessible public repositories. 
 
CRI iAtlas will provide a valuable resource for the cancer immunology field. The tools it provides 
will enable a range of users to quickly and easily access and visualize complex genomics and 
immunology data sets. The interface is user friendly and well documented, particularly for those 
without bioinformatics training.  
 
The detailed instructions certainly made it easier to understand what each tool did the first time I 
tried to use them. However, they also kind of clutter the interface. It would be nice to be able 
minimize those panels without minimizing the entire module. 
 
It would also be helpful to search the Driver Associations data for interactions involving certain 
genes of interest instead of having to scan through the volcano plots point by point. 
 
But those are minor quibbles. Overall this is a slick and powerful online tool that will be welcomed 
by the field.
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In this article, the authors introduce iAtlas, a web-based application that allows to browse a rich 
diversity of immune profiles, generated from the public TCGA dataset, and published in the 
landmark Immune Landscape study. 
Further than simply giving the possibility to replicate the published figures, the application 
provides a great flexibility to explore the entire PanImmune feature matrix through sophisticated 
and interactive tools.  
 
The modular architecture and the features of the software are clearly explained. Detailed 
instructions are provided. And, all the necessary information is given to run the application. 
Its source code repository on github is well structured. The documentation is very comprehensive, 
as it gives ample information on the underlying methods, as well as how to extend the software 
application. 
 
It is a very valuable resource for the Immuno-oncology community.
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